Making The Grade? Big Pharma Deals With Academia Begin To Score
With three to four years in the books, Big Pharma’s updated tie-ups with academia have started to progress – some have even reached first-in-human stages, but these updated models have yet to produce any radical results that show they are an improvement over old-style partnerships.
You may also be interested in...
What many high performing R&D organizations also share are fully integrated R&D sites, often in close vicinity to academic hotbeds
Silarus Therapeutics and Thyritope Biosciences are the latest two companies to be launched and financed by GlaxoSmithKline and partner Avalon Ventures. During Informa’s Pharmaceutical Strategy Conference, GSK’s Lon Cardon talks about how the partnership with Avalon is helping the Big Pharma access academic science.
Johnson & Johnson is nearing the completion of its network of early-stage innovation centers. IN VIVO talks to Patrick Verheyen of the year-old London hub to see where innovation centers fit into the J&J plan, and to Jimmy Zhang of the company’s soon-to-launch Shanghai branch about the climate for innovation in China and the wider Asia-Pacific region.